All Stories

  1. Sunitinib-induced hyperammonemic encephalopathy in metastatic gastrointestinal stromal tumors: A case report

    Article • World Journal of Clinical Cases, November 2023, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Yasuo Hamamoto

  2. MO34-1 Real-world evidence of precision medicine for biliary tract cancer

    Article • Annals of Oncology, November 2023, Elsevier

    Yasuo Hamamoto

  3. P57-2 Retrospective study of second-line FOLFOX versus S1 for advanced biliary tract cancer

    Article • Annals of Oncology, November 2023, Elsevier

    Yasuo Hamamoto

  4. 1649P Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer

    Article • Annals of Oncology, October 2023, Elsevier

    Yasuo Hamamoto

  5. 1546P Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer

    Article • Annals of Oncology, October 2023, Elsevier

    Yasuo Hamamoto

  6. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis

    Article • The Oncologist, August 2023, Oxford University Press (OUP)

    Yasuo Hamamoto

  7. Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)

    Article • British Journal of Cancer, August 2023, Springer Science + Business Media

    Yasuo Hamamoto, Hisato Kawakami

  8. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study

    Article • BMC Cancer, March 2023, Springer Science + Business Media

    Yasuo Hamamoto

  9. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program

    Article • JCO Precision Oncology, March 2023, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  10. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy

    Article • JCO Precision Oncology, May 2022, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  11. Management of elderly patients with esophageal squamous cell cancer

    Article • Japanese Journal of Clinical Oncology, April 2022, Oxford University Press (OUP)

    Yasuo Hamamoto

  12. Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

    Article • Clinical Cancer Research, March 2022, American Association for Cancer Research (AACR)

    Yasuo Hamamoto

  13. A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).

    Article • Journal of Clinical Oncology, February 2022, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  14. WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study).

    Article • Journal of Clinical Oncology, February 2022, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  15. Prospective feasibility study of indigo naturalis ointment for chemotherapy-induced oral mucositis

    Article • BMJ Supportive & Palliative Care, October 2021, BMJ

    Yasuo Hamamoto

  16. Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors

    Article • Scientific Reports, October 2021, Springer Science + Business Media

    Yasuo Hamamoto

  17. Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study

    Article • Gastric Cancer, September 2021, Springer Science + Business Media

    Yasuo Hamamoto

  18. A phase II study of chemoselection with docetaxel, cisplatin, and 5–fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).

    Article • Journal of Clinical Oncology, May 2021, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  19. Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)

    Article • Esophagus, May 2021, Springer Science + Business Media

    Yasuo Hamamoto

  20. Analysis of Risk Factors for Immune-Related Adverse Events in Various Solid Tumors Using Real-World Data

    Article • Future Oncology, April 2021, Taylor & Francis

    Yasuo Hamamoto

  21. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

    Article • Gastric Cancer, March 2021, Springer Science + Business Media

    Yasuo Hamamoto

  22. The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study

    Article • Diagnostics, March 2021, MDPI AG

    Yasuo Hamamoto

  23. Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.

    Article • Journal of Clinical Oncology, January 2021, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  24. FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.

    Article • Journal of Clinical Oncology, January 2021, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  25. Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up.

    Article • Journal of Clinical Oncology, January 2021, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  26. Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.

    Article • Journal of Clinical Oncology, January 2021, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  27. Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application

    Article • Cancer Science, January 2021, Wiley

    Yasuo Hamamoto

  28. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)

    Article • Esophagus, November 2020, Springer Science + Business Media

    Yasuo Hamamoto, Hisato Kawakami

  29. A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma

    Article • Japanese Journal of Clinical Oncology, November 2020, Oxford University Press (OUP)

    Yasuo Hamamoto

  30. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping

    Article • Cell, November 2020, Elsevier

    Yasuo Hamamoto

  31. Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

    Article • Annals of Surgery, October 2020, Wolters Kluwer Health

    Yasuo Hamamoto

  32. Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis

    Article • Digestive Diseases and Sciences, July 2020, Springer Science + Business Media

    Yasuo Hamamoto

  33. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II ...

    Article • BMC Cancer, June 2020, Springer Science + Business Media

    Yasuo Hamamoto

  34. <p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>

    Article • Cancer Management and Research, June 2020, Taylor & Francis

    Yasuo Hamamoto

  35. Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer

    Article • Cancer Science, April 2020, Wiley

    Yasuo Hamamoto

  36. Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites

    Article • Gastric Cancer, April 2020, Springer Science + Business Media

    Yasuo Hamamoto

  37. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    Article • Gastric Cancer, December 2019, Springer Science + Business Media

    Yasuo Hamamoto

  38. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

    Article • The Lancet Oncology, November 2019, Elsevier

    Yasuo Hamamoto

  39. A retrospective study of immune-related adverse events in various solid tumors

    Article • Annals of Oncology, October 2019, Elsevier

    Yasuo Hamamoto

  40. Clinical response to subsequent chemotherapy after nivolumab in patients with advanced gastric cancer

    Article • Annals of Oncology, October 2019, Elsevier

    Yasuo Hamamoto

  41. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer

    Article • Annals of Surgical Oncology, August 2019, Springer Science + Business Media

    Yasuo Hamamoto

  42. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia

    Article • JAMA Network Open, August 2019, American Medical Association (AMA)

    Yasuo Hamamoto

  43. Abstract 3882: Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer

    Article • Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Yasuo Hamamoto

  44. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer

    Article • Gastric Cancer, May 2019, Springer Science + Business Media

    Yasuo Hamamoto

  45. Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study

    Article • Journal of Patient-Reported Outcomes, May 2019, Springer Science + Business Media

    Yasuo Hamamoto

  46. Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review

    Article • BMC Nephrology, April 2019, Springer Science + Business Media

    Yasuo Hamamoto

  47. Prospective evaluation of a developed S-1 dosage formula based on renal function.

    Article • Journal of Clinical Oncology, February 2019, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  48. Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study

    Article • European Journal of Oncology Nursing, February 2019, Elsevier

    Yasuo Hamamoto

  49. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy...

    Article • Gastric Cancer, December 2018, Springer Science + Business Media

    Yasuo Hamamoto

  50. Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials

    Article • Clinical Colorectal Cancer, December 2018, Elsevier

    Yasuo Hamamoto

  51. Early administration of systemic chemotherapy should be�considered for scirrhous gastric cancer: A case report

    Article • Molecular and Clinical Oncology, November 2018, Spandidos Publications

    Yasuo Hamamoto

  52. Successful EUS-guided antegrade stenting for malignant severe biliary obstruction combined with a newly developed plastic stent

    Article • Endoscopy International Open, November 2018, Thieme Publishing Group

    Yasuo Hamamoto

  53. Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer

    Article • Annals of Oncology, October 2018, Elsevier

    Yasuo Hamamoto

  54. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors

    Article • Future Oncology, September 2018, Future Medicine

    Yasuo Hamamoto

  55. Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancer

    Article • Gastrointestinal Endoscopy, September 2018, Elsevier

    Yasuo Hamamoto

  56. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma

    Article • International Journal of Clinical Oncology, August 2018, Springer Science + Business Media

    Yasuo Hamamoto

  57. Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand–Foot Syndrome

    Article • Asia-Pacific Journal of Oncology Nursing, July 2018, Elsevier

    Yasuo Hamamoto

  58. Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma

    Article • Journal of Thoracic Disease, June 2018, AME Publishing Company

    Yasuo Hamamoto

  59. Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocar...

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  60. Pilot study of WT1 peptide‑pulsed dendritic cell vaccination with docetaxel in esophageal cancer

    Article • Oncology Letters, May 2018, Spandidos Publications

    Yasuo Hamamoto

  61. Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients

    Article • Asia-Pacific Journal of Oncology Nursing, April 2018, Elsevier

    Yasuo Hamamoto

  62. Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis

    Article • Investigational New Drugs, March 2018, Springer Science + Business Media

    Yasuo Hamamoto

  63. Treatment selection for esophageal cancer: evaluation from a nationwide database

    Article • Esophagus, February 2018, Springer Science + Business Media

    Yasuo Hamamoto

  64. Interaction between Medical Treatment and Minimally Invasive Surgical Treatment for the Malignancies of the Digestive Tract

    Article • Digestion, January 2018, Karger Publishers

    Yasuo Hamamoto

  65. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Article • The Lancet, December 2017, Elsevier

    Yasuo Hamamoto

  66. Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm

    Article • Gastric Cancer, October 2017, Springer Science + Business Media

    Yasuo Hamamoto

  67. Safety and efficacy of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer

    Article • Annals of Oncology, October 2017, Elsevier

    Yasuo Hamamoto

  68. Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer

    Article • International Journal of Clinical Oncology, July 2017, Springer Science + Business Media

    Yasuo Hamamoto

  69. Curative resectability of gastrointestinal cancer identified from iron deficiency anemia

    Article • Oncology Letters, July 2017, Spandidos Publications

    Yasuo Hamamoto

  70. Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report

    Article • Oncology Letters, July 2017, Spandidos Publications

    Yasuo Hamamoto

  71. Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma

    Article • Esophagus, May 2017, Springer Science + Business Media

    Yasuo Hamamoto

  72. A systemic review and meta-analysis to evaluate the efficacy and postprogression survival of second-line chemotherapy for gemcitabine-refractory pancreatic cancer.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  73. ABSOLUTE: A phase 3 trial of nanoparticle albumin-bound paclitaxel (nab-PTX) versus solvent-based paclitaxel (sb-PTX) in patients with pre-treated advanced gastric cancer (AGC)—Efficacy and QOL results.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  74. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

    Article • The Lancet Oncology, May 2017, Elsevier

    Yasuo Hamamoto

  75. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy

    Article • Cancer Chemotherapy and Pharmacology, February 2017, Springer Science + Business Media

    Yasuo Hamamoto

  76. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

    Article • Journal of Cancer Research and Clinical Oncology, February 2017, Springer Science + Business Media

    Yasuo Hamamoto

  77. Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo.

    Article • Journal of Clinical Oncology, February 2017, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  78. Serum HER2 level during chemotherapy as a biomarker for advanced gastric cancer.

    Article • Journal of Clinical Oncology, February 2017, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  79. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer

    Article • British Journal of Cancer, November 2016, Springer Science + Business Media

    Yasuo Hamamoto

  80. Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer

    Article • Annals of Oncology, October 2016, Elsevier

    Yasuo Hamamoto

  81. Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)

    Article • Oncology Letters, May 2016, Spandidos Publications

    Yasuo Hamamoto

  82. Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report

    Article • Oncology Letters, February 2016, Spandidos Publications

    Yasuo Hamamoto

  83. Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study

    Article • Japanese Journal of Clinical Oncology, January 2016, Oxford University Press (OUP)

    Yasuo Hamamoto

  84. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK)

    Article • Acta Oncologica, January 2016, Taylor & Francis

    Yasuo Hamamoto

  85. Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology Group

    Article • Japanese Journal of Clinical Oncology, December 2015, Oxford University Press (OUP)

    Yasuo Hamamoto

  86. Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report

    Article • Oncology Letters, November 2015, Spandidos Publications

    Yasuo Hamamoto

  87. Prognostic index model for overall survival in advanced unresectable pancreatic cancer from GEST study

    Article • Annals of Oncology, November 2015, Elsevier

    Yasuo Hamamoto

  88. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing reg...

    Article • Gastric Cancer, September 2015, Springer Science + Business Media

    Yasuo Hamamoto

  89. 2301 Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538) in Patients with Esophageal Cancer: Preliminary Report

    Article • European Journal of Cancer, September 2015, Elsevier

    Yasuo Hamamoto

  90. 2375 Prognostic index based on the phase III study of gemcitabine plus S-1, S-1 alone or gemcitabine alone in patients with advanced pancreatic cancer (GEST study)

    Article • European Journal of Cancer, September 2015, Elsevier

    Yasuo Hamamoto

  91. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study

    Article • Gastric Cancer, August 2015, Springer Science + Business Media

    Yasuo Hamamoto

  92. Development of dosing recommendation of S-1 for patients with impaired renal function by prospective pharmacokinetic study.

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  93. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)

    Article • European Journal of Cancer, May 2015, Elsevier

    Yasuo Hamamoto

  94. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

    Article • British Journal of Cancer, April 2015, Springer Science + Business Media

    Yasuo Hamamoto

  95. Phase I pilot study of Wilms tumor gene 1 peptide‐pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer

    Article • Cancer Science, March 2015, Wiley

    Yasuo Hamamoto

  96. Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy

    Article • Molecular and Clinical Oncology, February 2015, Spandidos Publications

    Yasuo Hamamoto

  97. An investigation of the safety of continued treatment with sorafenib in patients with unresectable hepatocellular carcinoma after the first disease progression: Multicenter, open-label, phase II safety study.

    Article • Journal of Clinical Oncology, January 2015, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  98. A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study)

    Article • The Oncologist, October 2014, Oxford University Press (OUP)

    Yasuo Hamamoto

  99. Neuroendocrine Tumor Evaluated as Pr by Treating 14 Months by Everolimus

    Article • Annals of Oncology, October 2014, Elsevier

    Yasuo Hamamoto

  100. Abstract 3146: Rac1 accumulates in the nucleus at the invasive front of colorectal cancer through promoting cell motility

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Yasuo Hamamoto

  101. Quality of Life in the Trastuzumab for Gastric Cancer Trial

    Article • The Oncologist, June 2014, Oxford University Press (OUP)

    Yasuo Hamamoto

  102. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy

    Article • International Journal of Clinical Oncology, April 2014, Springer Science + Business Media

    Yasuo Hamamoto

  103. Phase II study of neoadjuvant chemoradiotherapy with cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous cell carcinoma: A 2-year follow up.

    Article • Journal of Clinical Oncology, January 2014, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  104. Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms

    Article • The Journal of Clinical Pharmacology, January 2014, Wiley

    Yasuo Hamamoto

  105. Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 T...

    Article • Journal of Clinical Oncology, December 2013, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  106. A Phase II Study of the Panitumumab+ Irinotecan Therapy for Advanced / Recurrence Colorectal Cancer (Topic Study)

    Article • Annals of Oncology, November 2013, Elsevier

    Yasuo Hamamoto

  107. Retrospective Safety Analysis in Advanced Soft Tissue Sarcoma Patients of Pazopanib Hydrochloride

    Article • Annals of Oncology, November 2013, Elsevier

    Yasuo Hamamoto

  108. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma

    Article • Cancer Science, October 2013, Wiley

    Yasuo Hamamoto

  109. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912

    Article • Annals of Oncology, October 2013, Elsevier

    Yasuo Hamamoto

  110. Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106)

    Article • Japanese Journal of Clinical Oncology, September 2013, Oxford University Press (OUP)

    Yasuo Hamamoto

  111. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805)

    Article • Cancer Science, July 2013, Wiley

    Yasuo Hamamoto

  112. Case series of preoperative triplet-regimen (docetaxel, CDDP and 5-fluorouracil) for borderline resectable T4 thoracic esophageal carcinoma

    Article • Esophagus, July 2013, Springer Science + Business Media

    Yasuo Hamamoto

  113. Abstract 4064: Rac1 activation promotes invasive phenotype of side population in colon cancer cells by destabilizing the E cadherin-β-catenin ligation.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Yasuo Hamamoto

  114. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells

    Article • Cancer Science, January 2013, Wiley

    Yasuo Hamamoto

  115. Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature

    Article • Oncology Letters, October 2012, Spandidos Publications

    Yasuo Hamamoto

  116. Randomized Phase II Trial of Gemcitabine Plus S-1 Combination Therapy Versus S-1 in Advanced Biliary Tract Cancer: Results of the Japan Clinical Oncology Group Study (JCOG0805)

    Article • Annals of Oncology, October 2012, Elsevier

    Yasuo Hamamoto

  117. Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

    Article • Gastric Cancer, July 2012, Springer Science + Business Media

    Yasuo Hamamoto

  118. Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phen...

    Article • Journal of Gastroenterology, May 2012, Springer Science + Business Media

    Yasuo Hamamoto

  119. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells

    Article • Gastric Cancer, April 2012, Springer Science + Business Media

    Yasuo Hamamoto

  120. Feasibility study of neoadjuvant chemoradiotherapy with cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous cell carcinoma.

    Article • Journal of Clinical Oncology, February 2012, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  121. Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805).

    Article • Journal of Clinical Oncology, February 2012, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  122. Regional differences in patient (pt) characteristics of AVAGAST: An exploratory comparison in chemotherapy plus placebo (PL) arm between Japanese (JPN) and the rest of the world (ROW) pts.

    Article • Journal of Clinical Oncology, February 2012, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  123. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

    Article • Gastric Cancer, December 2011, Springer Science + Business Media

    Yasuo Hamamoto

  124. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer

    Article • Cancer Chemotherapy and Pharmacology, November 2011, Springer Science + Business Media

    Yasuo Hamamoto

  125. Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma

    Article • International Journal of Clinical Oncology, March 2011, Springer Science + Business Media

    Yasuo Hamamoto

  126. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

    Article • Investigational New Drugs, January 2011, Springer Science + Business Media

    Yasuo Hamamoto

  127. Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1

    Article • Japanese Journal of Clinical Oncology, October 2010, Oxford University Press (OUP)

    Yasuo Hamamoto

  128. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

    Article • Cancer Chemotherapy and Pharmacology, August 2010, Springer Science + Business Media

    Yasuo Hamamoto

  129. Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer

    Article • Japanese Journal of Clinical Oncology, May 2010, Oxford University Press (OUP)

    Yasuo Hamamoto

  130. Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer

    Article • Journal of Clinical Oncology, April 2010, American Society of Clinical Oncology (ASCO)

    Yasuo Hamamoto

  131. Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506

    Article • Japanese Journal of Clinical Oncology, February 2010, Oxford University Press (OUP)

    Yasuo Hamamoto

  132. A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer

    Article • Japanese Journal of Clinical Oncology, March 2009, Oxford University Press (OUP)

    Yasuo Hamamoto

  133. Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer

    Article • International Journal of Clinical Oncology, April 2008, Springer Science + Business Media

    Yasuo Hamamoto

  134. A case of multiple protruding and flat colorectal tumors analyzed by a cDNA array

    Article • International Journal of Colorectal Disease, August 2005, Springer Science + Business Media

    Yasuo Hamamoto

  135. A case of pneumatosis cystoides intestinalis with dermatomyositis in which EUS was useful for the diagnosis

    Article • International Journal of Colorectal Disease, November 2004, Springer Science + Business Media

    Yasuo Hamamoto

  136. A case of colorectal carcinoma in adenoma analyzed by a cDNA array

    Article • International Journal of Colorectal Disease, October 2004, Springer Science + Business Media

    Yasuo Hamamoto

  137. Usefulness of narrow-band imaging endoscopy for diagnosis of Barrett?s esophagus

    Article • Journal of Gastroenterology, January 2004, Springer Science + Business Media

    Yasuo Hamamoto

  138. A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms

    Article • Gastrointestinal Endoscopy, April 2002, Elsevier

    Yasuo Hamamoto